Alternative Surveillance Program for Patients With High Risk Group of HCC
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Dec 10, 2022
Trial Information
Current as of January 14, 2025
Active, not recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • chronic hepatitis B or C
- • Child-Pugh classification A
- • HCC risk score \>= -2.04
- • have not diagnosed with HCC
- • on surveillance program using US and negative on previous US within 6-8 months of enrollment
- • sign informed consent
- Exclusion Criteria:
- • younger than 40 years or older than 70 years old
- • history of HCC
- • severe GFR or on HD/PD due to renal failure
- • contra-indication of MRI
- • congestive hepatopathy
- • iron deposition
- • pregnancy or nursing mother
- • non-viral hepatitis or liver cirrhosis
Trial Officials
Jeong Hee Yoon, MD
Principal Investigator
Seoul National University Hospital
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials